Marc Goodman
Stock Analyst at Leerink Partners
(2.91)
# 1,632
Out of 4,948 analysts
92
Total ratings
56.16%
Success rate
26.85%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $15.71 | +218.27% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $8.00 | +25.00% | 5 | May 7, 2025 | |
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $109.22 | +37.34% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $0.66 | +51.75% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $37.85 | -15.46% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $66.63 | -62.48% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $14.70 | +240.14% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $6.73 | +197.18% | 3 | Jan 19, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $132.90 | -13.47% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $138.60 | +123.67% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $13.69 | -12.34% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $38.23 | +20.32% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $25.33 | -17.09% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $117.77 | +78.31% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.13 | +369.48% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $29.05 | -7.06% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.39 | +178.29% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $521.00 | -48.18% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $206.69 | -53.55% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.44 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $84.21 | -20.44% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $22.70 | +331.72% | 7 | Oct 5, 2017 |
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $15.71
Upside: +218.27%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $8.00
Upside: +25.00%
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $109.22
Upside: +37.34%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $0.66
Upside: +51.75%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $37.85
Upside: -15.46%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $66.63
Upside: -62.48%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $14.70
Upside: +240.14%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $6.73
Upside: +197.18%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $132.90
Upside: -13.47%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $138.60
Upside: +123.67%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $13.69
Upside: -12.34%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $38.23
Upside: +20.32%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $25.33
Upside: -17.09%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $117.77
Upside: +78.31%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.13
Upside: +369.48%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $29.05
Upside: -7.06%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.39
Upside: +178.29%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $521.00
Upside: -48.18%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $206.69
Upside: -53.55%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $48.44
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $84.21
Upside: -20.44%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $22.70
Upside: +331.72%